Background Age-related macular degeneration (AMD) is thought to cause approximately 9%
of all cases of blindness worldwide. In Germany, half of all cases of blindness and high …

Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

Purpose To apply a deep learning algorithm for automated, objective, and comprehensive
quantification of optical coherence tomography (OCT) scans to a large real-world dataset of …

Objectives To study the effect of repeated retinal thickness fluctuations during the anti-VEGF
therapy maintenance phase in neovascular age-related macular degeneration (nAMD) …

Purpose: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg
in treatment-naive patients with neovascular age-related macular degeneration enrolled in …

Purpose To quantify the shrinking in outpatient and intravitreal injections' volumes in a
tertiary referral retina unit secondary to virus causing coronavirus disease 2019 (COVID-19) …

Purpose Characterize real-world baseline visual acuity (VA) and anti-vascular endothelial
growth factor (VEGF) treatment patterns in neovascular age-related macular degeneration …

Purpose To estimate the impact of delayed care during the coronavirus disease 2019
(COVID-19) pandemic on the outcomes of patients with neovascular age-related macular …

Purpose Intravitreal injection of VEGF inhibitors has become the standard of care for
different macular diseases within the last years resulting in improved visual outcomes …

Purpose Single center, noninterventional cohort study to assess 10-year visual and
anatomical outcomes following initiation of treatment with antivascular endothelial growth …